NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis $2.78 +0.02 (+0.72%) As of 08/21/2026 09:39 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About XTL Biopharmaceuticals Stock (NASDAQ:XTLB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XTL Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$2.78▼$2.7850-Day Range$2.30▼$3.2352-Week Range$2.01▼$10.28Volume516 shsAverage Volume10,791 shsMarket Capitalization$6.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. Read More XTL Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreXTLB MarketRank™: XTL Biopharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXTL Biopharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXTL Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about XTL Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XTL Biopharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XTL Biopharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of XTL Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXTL Biopharmaceuticals has a short interest ratio ("days to cover") of 6.97.Change versus previous monthShort interest in XTL Biopharmaceuticals has recently decreased by 32.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXTL Biopharmaceuticals does not currently pay a dividend.Dividend GrowthXTL Biopharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for XTL Biopharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.40% of the stock of XTL Biopharmaceuticals is held by institutions.Read more about XTL Biopharmaceuticals' insider trading history. Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XTLB Stock News HeadlinesXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average - Here's What HappenedAugust 20 at 3:20 AM | americanbankingnews.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average - Should You Sell?August 12, 2026 | americanbankingnews.comBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.August 22 at 1:00 AM | TradeSmith (Ad)XTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comXTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comXTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQXTL Completed the Acquisition of Psyga Bio Ltd.June 30, 2026 | globenewswire.comXTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026June 23, 2026 | tipranks.comSee More Headlines XTLB Stock Analysis - Frequently Asked Questions How have XTLB shares performed this year? XTL Biopharmaceuticals' stock was trading at $2.3040 at the beginning of 2026. Since then, XTLB shares have increased by 20.7% and is now trading at $2.78. How were XTL Biopharmaceuticals' earnings last quarter? XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) issued its quarterly earnings results on Tuesday, June, 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The biopharmaceutical company earned ($0.26) million during the quarter. When did XTL Biopharmaceuticals' stock split? XTL Biopharmaceuticals's stock reverse split on the morning of Wednesday, March 25th 2026.The 1-4 reverse split was announced on Friday, March 20th 2026. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 24th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of XTL Biopharmaceuticals? Shares of XTLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP). Company Calendar Last Earnings6/30/2026Today8/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 XTLB's financial health is in the Green zone, according to TradeSmith. XTLB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XTLB CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$450 thousand Price / Sales13.59 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-23.17Miscellaneous Outstanding Shares2,200,000Free Float1,565,000Market Cap$6.12 million OptionableNot Optionable Beta1.46 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:XTLB) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA Worldwide Gold Lockdown Is Now UnderwayGold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts